Having pasta for dinner this weekend? This one trick can make it healthier
Pasta is a carbohydrate-rich food, made primarily of flour, butter and cheese. For weight watchers and diabetics, it is a no-go — unless we find a trick to make it healthier. While scrolling through the internet, we came across a post that shared an easy hack to make your favourite dish a guilt-free indulgence.
Pasta's high glycaemic index increases the risk of diabetes and weight gain, but if you cook it and refrigerate it once cool, it becomes a source of resistant starch. 'Cooking and cooling the pasta for at least 7-8 hours can make it a lot more healthier and better for over all health! It increases resistant starch, which is beneficial for you!' said Mumbai-based nutritionist Deepsikha Jain.
According to her, resistant starch is easier to digest and reduces the overall calorie count of the dish by 30-50%. It also increases the fiber content which makes it a great source of food for all those who have diabetes and a trying to lose weight.
The expert noted that:
Resistant starch also has a lower glycemic index. It promotes satiety, reduces impact on postprandial blood glucose levels as compared to easily digestible carbs, improves insulin sensitivity. It works as a prebiotic, improves absorption of minerals and boosts liver function. This makes resistant starch a preferable choice for diabetes, insulin resistance, obesity, metabolic syndrome, gut health and immunity.
Concurring, Dr Vidhi Dhingra, Senior Dietician, vHealth by Aetna told indianexpress.com that if we include these foods in moderation and try the cooling post-cooking rule, it helps in increasing resistant starch which may reduce the glycemic index and, in turn, improve insulin sensitivity.
'Cooking and cooling for 8-10 hours can indeed help you. Cooled pasta has more than two times the amount of resistant starch than freshly cooked pasta. The resistance starch helps boost gut health, which means an increase in the good bacteria that help decrease levels of constipation. It also improves the body's ability to respond to insulin. This means lower risk of insulin resistance and its accompanying chronic diseases like type 2 diabetes,' functional nutritionist Mugdha Pradhan, CEO and Founder, iThrive, added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
Army unveils oxygen plant for high-altitude emergencies in Arunachal's Tawang
GUWAHATI The Indian Army has unveiled an oxygen generation plant for high-altitude emergencies in western Arunachal Pradesh's Tawang. The plant at the Military Hospital in Tawang was engineered for rapid deployment and optimal efficiency under extreme conditions. It is a self-contained unit capable of generating medical-grade oxygen round the clock. The facility, built with contributions from the Soldiers' Independent Rehabilitation Foundation, a Pune-based NGO, was commissioned by the General Officer Commanding of the Gajraj Corps' Ball of Fire Division on Thursday (June 5, 2025). The plant would 'serve as a critical life-saving facility for both the armed forces personnel and local civilian populations, especially in the strategically sensitive and geographically challenging terrain of the region,' a Defence Ministry statement said. Most of the habitations in Tawang district are at an altitude of at least 10,000 ft. above mean sea level. Oxygen levels are low in these places. On June 3, the Army's Spear Corps carried out a major civic outreach initiative under Operation Sadbhavana in the Ziro Valley in Arunachal Pradesh's Lower Subansiri district. The activities included the distribution of stationery kits to primary school children, the installation of mobile toilet cubicles to improve public hygiene and sanitation, and the establishment of open-air gym equipment to promote fitness and community well-being.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad-based drug major has entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets, Dr Reddy's Laboratories said in a statement. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were USD 29.5 billion. The collaboration combines Dr Reddy's and Alvotech's proven capabilities in biosimilars thereby speeding up the development process and extending the global reach for this biosimilar candidate, the company noted. "It further enables us to increase the availability of cost-effective, critical biologic medications to patients world-wide," he added. Dr Reddy's shares were trading 3.49 per cent up at Rs 1,295.80 apiece on BSE.
New Indian Express
4 hours ago
- New Indian Express
Dr Reddy's–Alvotech deal: Why investors are bullish
CHENNAI: Shares of Dr Reddy's Laboratories surged over 3% in early trade on Thursday after the Indian drug maker announced a global licensing agreement with Alvotech, an Iceland-based biopharmaceutical company. Under this agreement, the two firms will codevelop, manufacture, and commercialise a biosimilar candidate to Keytruda (called as pembrolizumab by the biological name) — a blockbuster cancer immunotherapy drug originally developed by the US pharma major Merck & Co., also known as MSD Pharmaceuticals outside US. Keytruda, prescribed for the treatment of various cancers including melanoma, non-small cell lung cancer, and head and neck cancers, in adults and children, is one of the most sold drugs of Merck from its original research. According to Merck's 2024 sales data, this drug alone contributed over $29.5 billion in revenue for the company, which also makes it one of the world's top-selling drugs. This drug is in demand as it is used in advanced, metastatic, or recurrent cancers that are not responding to other treatments or cannot be removed by surgery. Keytruda can also be used to prevent cancer recurrence after surgery. A biosimilar is a generic equivalent of a biological drug. In this case, the biosimilar -- pembrolizumab-- can enter the market once Merck's patent is expired. There are several drug firms work on this bio-molecule currently worldwide, and Alvotech is one of the frontrunners. The licensing deal signed between Dr Reddy's and Alvotech marks a strategic expansion of the former's biosimilars pipeline, aligning with the company's ambition to build a strong presence in the global oncology space.
